scholarly journals Writing Clinical Papers. The Heart of the Matter

2016 ◽  
Vol 2 (3) ◽  
pp. 104-105
Author(s):  
Ario Santini
Keyword(s):  
Author(s):  
Heinz Fankhauser ◽  
Patrick R. Gavin
Keyword(s):  

2020 ◽  
Vol 17 (2) ◽  
Author(s):  
Hossein Beydokhti ◽  
Nosrat Riahinia ◽  
Hamid R Jamali ◽  
Saeid Asadi ◽  
Seyed Mohammad Riahi

Background: Level of evidence (LoE) is a hierarchical system for classifying the quality of studies. Objectives: This study examined the factors affecting the number of citations to clinical articles related to the treatment of human diseases that have included the LoE in their abstracts. Methods: A total of 3,683 therapeutic articles published between 2011 and 2013 that mentioned the LoE in their abstract and were indexed in PubMed and Web of Science were retrieved. The LoE and type of study design were extracted from abstracts and other bibliographic and citation information was obtained from PubMed and Web of Science databases. Independent samples t-test, one-way ANOVA, Pearson correlation test and linear regression were used to analyze the relationship between the variables. Results: Articles with level I evidence had the lowest frequency (290, 7.9%) and articles with level IV had the highest frequency (1,831, 49.7%). Five-year citations ranged from zero to 215, with a median of 13 citations. The median values of five-year citations from level I to level V were 20.5, 15, 14, 11, and 6 citations, respectively. Evaluation of the models to examine the factors affecting the number of citations showed that the change of evidence-level from level I to V reduced the number of citations (P < 0.001). Conclusions: Journal Impact Factor, LoE, number of references, number of authors, number of title words, number of pages, article type and subject category accounted for about 25% of the variation in five-year citations of clinical papers. Clinical papers with high LoE (levels I & II) received more citations over a five-year period than those with lower LoE (levels III & IV).


1997 ◽  
Vol 8 ◽  
pp. S5-S6
Author(s):  
R. Stupp ◽  
S.T. Ong ◽  
J.E. Ultmann
Keyword(s):  

1997 ◽  
Vol 26 (3) ◽  
pp. 113-114
Author(s):  
Harold L. Rekate
Keyword(s):  

Digestion ◽  
1990 ◽  
Vol 47 (1) ◽  
pp. 53-53
Author(s):  
W. Creutzfeldt
Keyword(s):  

2016 ◽  
Vol 2016 ◽  
pp. 1-13 ◽  
Author(s):  
M. Sean Peach ◽  
Daniel M. Trifiletti ◽  
Bruce Libby

Prostate cancer is the most common malignancy found in North American and European men and the second most common cause of cancer related death. Since the practice of PSA screening has become common the disease is most often found early and can have a long indolent course. Current definitive therapy treats the whole gland but has considerable long-term side effects. Focal therapies may be able to target the cancer while decreasing dose to organs at risk. Our objective was to determine if focal prostate brachytherapy could meet target objectives while permitting a decrease in dose to organs at risk in a way that would allow future salvage treatments. Further, we wanted to determine if focal treatment results in less toxicity. Utilizing the Medline repository, dosimetric papers comparing whole gland to partial gland brachytherapy and clinical papers that reported toxicity of focal brachytherapy were selected. A total of 9 dosimetric and 6 clinical papers met these inclusion criteria. Together, these manuscripts suggest that focal brachytherapy may be employed to decrease dose to organs at risk with decreased toxicity. Of current technology, image-guided HDR brachytherapy using MRI registered to transrectal ultrasound offers the flexibility and efficiency to achieve such focal treatments.


2002 ◽  
Vol 10 (1) ◽  
pp. 57
Author(s):  
Wendy Fairhurst
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document